Literature DB >> 26824946

Is Aerosolized Pentamidine for Pneumocystis Pneumonia Prophylaxis in Renal Transplant Recipients Not as Safe as We Might Think?

N Macesic1, K Urbancic2, F Ierino3, M L Grayson4.   

Abstract

Outbreaks ofPneumocystispneumonia have been described in renal transplant recipients. Aerosolized pentamidine is frequently used for prophylaxis in this setting. We report our experience with aerosolized pentamidine use in 56 renal transplant recipients. We found high rates of adverse reactions in patients with chronic respiratory disease.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26824946      PMCID： PMC4808234          DOI： 10.1128/AAC.02290-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

Authors:  Andrew H Limper; Kenneth S Knox; George A Sarosi; Neil M Ampel; John E Bennett; Antonino Catanzaro; Scott F Davies; William E Dismukes; Chadi A Hage; Kieren A Marr; Christopher H Mody; John R Perfect; David A Stevens
Journal:  Am J Respir Crit Care Med       Date:  2011-01-01       Impact factor: 21.405

2.  Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients.

Authors:  K Saukkonen; R Garland; H Koziel
Journal:  Chest       Date:  1996-05       Impact factor: 9.410

3.  Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients.

Authors:  Nicos Mitsides; Kerry Greenan; Darren Green; Rachel Middleton; Elizabeth Lamerton; Judith Allen; Jane Redshaw; Paul R Chadwick; Chinari Pk Subudhi; Grahame Wood
Journal:  Nephrology (Carlton)       Date:  2014-03       Impact factor: 2.506

4.  Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients.

Authors:  Lisa M Phipps; Sharon C-A Chen; Kathy Kable; Catriona L Halliday; Carolina Firacative; Wieland Meyer; Germaine Wong; Brian J Nankivell
Journal:  Transplantation       Date:  2011-12-27       Impact factor: 4.939

5.  An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?

Authors:  Mark G J de Boer; Lesla E S Bruijnesteijn van Coppenraet; Andre Gaasbeek; Stefan P Berger; Luc B S Gelinck; Hans C van Houwelingen; Peterhans van den Broek; Ed J Kuijper; Frank P Kroon; Jan P Vandenbroucke
Journal:  Clin Infect Dis       Date:  2007-03-26       Impact factor: 9.079

6.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.

Authors:  C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

7.  A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii.

Authors:  Solène Le Gal; Céline Damiani; Amélie Rouillé; Anne Grall; Laetitia Tréguer; Michèle Virmaux; Elodie Moalic; Dorothée Quinio; Marie-Christine Moal; Christian Berthou; Philippe Saliou; Yann Le Meur; Anne Totet; Gilles Nevez
Journal:  Clin Infect Dis       Date:  2012-02-14       Impact factor: 9.079

Review 8.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Utility of inhaled pentamidine prophylaxis in lung transplant recipients.

Authors:  S D Nathan; D J Ross; P Zakowski; R M Kass; S K Koerner
Journal:  Chest       Date:  1994-02       Impact factor: 9.410

10.  Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients.

Authors:  Su Young Kim; Alix A Dabb; Donald J Glenn; Kristen M Snyder; Meredith K Chuk; David M Loeb
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167
View more
  3 in total

1.  Taking the challenge: A protocolized approach to optimize Pneumocystis pneumonia prophylaxis in renal transplant recipients.

Authors:  K F Urbancic; F Ierino; E Phillips; P F Mount; A Mahony; J A Trubiano
Journal:  Am J Transplant       Date:  2017-10-03       Impact factor: 8.086

2.  Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.

Authors:  Melissa Quinn; J T Fannin; Joseph Sciasci; Allison Bragg; Patrick K Campbell; Delia Carias; Kristine R Crews; David Gregornik; Sima Jeha; Gabriela Maron; Jennifer L Pauley; Hope D Swanson; Joshua Wolf; William Greene
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 3.  Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.

Authors:  John G Rizk; Jose G Lazo; David Quan; Steven Gabardi; Youssef Rizk; Elani Streja; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Rev Endocr Metab Disord       Date:  2021-07-22       Impact factor: 6.514
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.